Anteris Technologies Ltd Appoints Highly Experienced Chief Medical Officer

The appointment of Dr. Meduri, a recognized leader in the field of heart valve disease, should strengthen the credibility of Anteris’ DurAVR ™ aortic replacement valve.

Anteris Technologies Ltd (ASX: AVR, OTC: AMEUF, FRA: DDF) has appointed internationally renowned interventional cardiologist, Dr Chris Meduri MD MPH, as Chief Medical Officer (CMO).

Anteris is a company with a structural heart that develops next-generation technologies that help healthcare professionals create life-changing outcomes for patients.

The appointment of Dr. Meduri, a recognized leader in the field of heart valve disease, should strengthen the credibility of Anteris’ DurAVR ™ aortic replacement valve.

DurAVR ™ is developed to meet the acute needs for a superior hemodynamic profile as well as the chronic needs in its ability to maintain this profile longer throughout the patient’s life.

The right time for a CMO

Dr Meduri has been the National Principal Investigator of several valve trials and served on numerous steering committees and performed groundbreaking procedures in the United States and around the world, led recruitment in numerous trials, and actively participated in 11 first. catheter feasibility studies.

“With the rapid progress of the DurAVR ™ program, now is the time just before our first planned feasibility study to establish the role of CMO,” said Wayne Paterson, CEO of Anteris.

“Chris worked as a member of the advisory board so his transition to the Marketing Director position will be smooth.

“While retaining outpatient clinical practice responsibilities, the additional time he devotes to this new role will help us go even further while adding greater credibility and profile to our product.

“Chris is well known and respected within the global cardiology community. We are delighted that he has accepted to be our Marketing Director. “

Rendezvous already knows the company

Dr Meduri has been an active member of the Anteris Medical Advisory Board since its inception and has already contributed significantly to the current progress in the development of DurAVR ™.

The experience with DurAVR ™ and the extra attention Dr Meduri will bring should prove invaluable to Anteris as he continues to ramp up his feasibility study.

Dr. Meduri’s reputation may also play a role in the recognition of Anteris within the medical community.

He has performed over 1,500 transcatheter aortic valve replacement (TAVR) procedures using all currently available products, helped create postoperative care pathways for TAVR patients, and developed an application used to optimize the care of TAVR patients.

TAVR procedures replace a diseased aortic valve with an artificial valve.

“I am honored to take on a larger role within the Anteris team to help them fulfill their mission to provide the most durable heart valve in the world. I look forward to working with the talented team and advisory board to launch the DurAVR ™ product and help deliver a more sustainable TAVR future for all patients, ”said Dr. Meduri.

Dr. Meduri is widely published in areas such as TAVR, mitral valve repair and replacement, tricuspid repair and more.

He is also an active speaker and live case operator at many major international conferences in cardiology and medicine.

Meduri completed his general, interventional and structural training in heart disease at Beth Israel Deaconess Medical Center, Harvard Medical School and completed his Masters of Public Health (MPH) with a specialization in clinical efficacy at the Harvard School of Public Health. He completed his internship and residency in internal medicine at Duke University.